Aarti Pharmalabs Peer Comparison

NSE: AARTIPHARM | BSE: 543748

₹840.70

₹27.20 (3.34%)

As on 28-Aug-2026IST

Market cap

₹7,613 Cr

Revenue (TTM)

₹1,969 Cr

P/E Ratio

35.7

P/B Ratio

3.5

Div. Yield

0.4 %

Edit

	Aarti Pharmalabs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Market cap (₹ Cr)	7,613	32,104	29,892	29,103	26,871
Revenue (₹ Cr)	1,969	3,564	1,936	9,205	1,462
Net Profit (₹ Cr)	195.95	414.00	288.22	-371.81	387.35
Net Margin (%)	9.91	11.23	14.79	-3.93	26.01
RoE (%)	10.33	8.38	29.77	-3.85	25.18
Price to Earnings	35.72	78.49	103.71	--	69.57
Price-To-Book	3.47	6.38	22.27	3.64	15.55

Income Statement (₹ Cr)

	Aarti Pharmalabs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Operating Revenue	1,969.05	3,564.00	1,935.80	9,205.28	1,461.80
Total Income	1,977.23	3,686.00	1,948.58	9,449.59	1,489.25
Total Expenditure	1,542.78	2,792.00	1,485.56	8,195.15	919.25
EBITDA	426.27	772.00	450.24	1,010.13	542.56
Depreciation	111.57	226.00	50.83	857.51	37.68
EBIT	314.70	546.00	399.41	152.62	504.88
Interest	52.98	217.00	40.84	342.73	3.77
Other Income	8.18	122.00	12.78	244.31	27.45
Exceptional Items	-2.80	12.00	0.00	-216.88	0.00
Profit before Tax	267.10	463.00	371.35	-162.68	528.56
Provision for Tax	71.16	49.00	83.14	209.13	141.21
Profit after Tax	195.95	414.00	288.22	-371.81	387.35

	Aarti Pharmalabs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Shareholder's Funds	2,124.61	4,940.00	1,288.82	8,162.62	1,653.56
Minority Interest	0.00	-5.00	0.00	0.00	-1.13
Non-Current Liabilities	419.53	1,712.00	202.03	5,044.14	42.40
Current Liabilities	937.57	1,622.00	835.87	4,758.28	230.82
Total Liabilities	2,906.41	8,100.00	1,451.43	15,513.53	1,549.26

	Aarti Pharmalabs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Non-Current Assets	1,966.64	5,343.00	519.60	10,211.52	1,026.85
Current Assets	1,397.29	2,606.00	1,681.81	7,191.66	881.27
Total Assets	2,906.41	8,100.00	1,451.43	15,513.53	1,549.26
Total Debt*	396.35	1,859.00	393.17	4,720.27	8.18
Net Current Assets	459.72	984.00	845.94	2,433.38	650.46
Contingent Liabilities	13.91	770.26	12.25	99.76	15.38

	Aarti Pharmalabs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Cash From Operating Activities	331.56	-22.00	159.18	892.30	118.34
Cash Flow from Investing Activities	-413.90	-783.00	-64.81	-477.46	-223.94
Cash from Financing Activities	65.44	409.00	-39.81	-440.83	261.12
Net Cash Inflow / Outflow	-16.90	-396.00	54.56	-25.99	155.52

	Aarti Pharmalabs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
ROCE (%)	17.59	4.07	26.97	6.61	20.14
ROE (%)	10.33	8.38	29.77	-3.85	25.18
ROA (%)	6.13	4.94	24.77	-2.21	21.93
EBIT Margin (%)	15.98	15.32	20.63	1.66	34.54
Net Margin (%)	9.91	11.23	14.79	-3.93	26.01
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Aarti Pharmalabs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Revenue Growth (%)	1.20	18.37	46.65	0.78	40.90
EBIT Growth (%)	-14.33	252.26	62.13	-70.53	124.50
Net Profit Growth (%)	-26.00	377.85	89.49	-1,383.43	104.15
EPS Growth (%)	-18.10	1,001.33	78.60	-484.84	42.32
Book Value Growth (%)	13.17	29.77	42.49	2.28	94.96

	Aarti Pharmalabs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Price / Earnings	35.32	80.56	102.12	-93.01	69.57
Price / Book Value	3.47	6.38	22.27	3.64	15.55
Dividend Yield (%)	0.42	0.00	0.08	0.00	0.08
EV/EBITDA	18.66	43.48	66.20	32.91	49.08
Market Cap (₹ Cr)	6,784.52	23,064.69	0.00	29,731.27	19,988.69

	Aarti Pharmalabs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debt to Equity	0.09	0.31	0.11	0.53	0.01
Short term debt to equity ratio	0.15	0.11	0.54	0.12	0.02
Current Ratio	1.49	1.61	2.01	1.51	3.82
Quick Ratio	0.81	1.06	1.14	0.87	2.82
Interest Coverage	6.04	3.13	10.09	0.53	141.16

	Aarti Pharmalabs	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debtors to sales (%)	29.62	16.50	26.28	23.44	24.80
Asset Turnover	0.62	0.43	1.66	0.55	0.83
Receivable days	94.46	60.36	47.59	77.05	90.06
Inventory Days	106.17	64.42	62.58	77.13	61.02
Payable days	106.17	218.94	228.78	173.49	96.06
Cash Conversion Cycle	94.46	-94.15	-118.62	-19.30	55.02

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.